06 / Supply & Regulation
Research-grade and medical-grade, what the labels mean
Reference documentation on how these compounds are regulated, supplied and studied. Not a vendor assessment, not a recommendation, and not personal-use instructions.
Neither phrase is a grade. "Medical-grade" has no definition in United States drug law at all, and "research-grade" describes how a product is marketed rather than how pure it is. The distinction that carries legal and manufacturing weight is between supply lanes: an approved finished drug made under current Good Manufacturing Practice, a preparation compounded by a licensed pharmacy or a registered outsourcing facility, and a substance sold for laboratory use under a not-for-human-consumption label. The table below places every compound in this catalog in one of those lanes.
| Supply lane | Count | What the lane means |
|---|---|---|
| Approved prescription drug | 14 | A regulator has approved a finished drug containing the compound. It is made under current Good Manufacturing Practice against a filed specification, and it carries an approved label stating indications, dosing and contraindications.For example: Tirzepatide, Semaglutide, Tesamorelin, Somatropin (HGH). |
| Approved outside the United States | 3 | Approved by a regulator elsewhere, with no United States approval. The approval is real, but it was granted against another standard and no FDA label exists.For example: Semax, Selank, Cerebrolysin. |
| Compounding lane | 14 | No approved finished drug, but a history of being compounded by pharmacies. Whether that is lawful turns on the FDA bulk drug substance lists rather than on purity.For example: BPC-157, TB-500, CJC-1295, Ipamorelin. |
| In clinical trials, not approved | 9 | Under formal study. The only supply a regulator recognises is the trial itself.For example: Retatrutide, SS-31, Kisspeptin-10, ARA-290. |
| Cosmetic ingredient | 16 | Sold in topical cosmetic products. Cosmetic ingredients are not reviewed or approved before sale in the United States, and a cosmetic claim is not a drug claim.For example: GHK-Cu, AHK-Cu, Argireline, Decapeptide-12. |
| Supplement or clinic-administered | 2 | Sold as a dietary supplement or administered at a clinic. Supplements are not approved before sale and the manufacturer, not a regulator, is responsible for the claims.For example: Glutathione, NAD+. |
| Research chemical only | 51 | Sold for laboratory use under a not-for-human-consumption label. No regulator has evaluated identity, purity or safety for human use, and the label is what keeps the sale outside drug regulation.For example: AOD-9604, MOTS-C, MK-677, IGF-1 LR3. |
| Not established | 1 | The catalog cannot place it, which is itself the finding.For example: DS5. |
Why the two words survive
Both terms do useful commercial work and no regulatory work. "Medical-grade" signals quality without committing to a standard, which is why it appears on products a regulator has never assessed. "Research-grade" and the not-for-human-consumption label attached to it are the mechanism by which a substance is sold at all: labelling a compound for laboratory use keeps the sale outside drug regulation, because the product is not being offered as a medicine. That is a statement about intended use, not about what is in the vial.
What a certificate of analysis establishes, and what it does not
A certificate of analysis typically reports purity by high-performance liquid chromatography and identity by mass spectrometry. Both are meaningful, and a source that will not supply one is worse than a source that will. Neither establishes sterility, endotoxin load, correct fill weight, or stability of the material actually shipped, and a certificate describes the lot it was drawn from rather than the vial in hand.
- HPLC purity states the proportion of the sample that is the intended peptide. It does not identify what the remainder is.
- Mass spectrometry confirms molecular weight, which is strong evidence of identity and silent on contamination.
- Sterility and bacterial endotoxin are separate tests and are frequently absent from a research-chemical certificate.
- A certificate supplied by the seller rather than by an independent laboratory is an assertion, not an audit.
Where the compounding lane actually stands
For compounds with no approved drug, the practical question is whether a pharmacy may lawfully use the bulk substance. FDA answers that through its 503A and 503B bulk drug substance lists, and it publishes the substances it considers to present significant safety risks by name. The lists below are the join between that record and this catalog. A substance in category 2 has been evaluated and flagged. A substance on the withdrawn list was nominated, flagged, and then the nomination was withdrawn by whoever filed it, which leaves it with no route to lawful compounding rather than with a clean record.
| Compound | Lane | Date FDA added it |
|---|---|---|
| GHRP-2 | 503B | September 29, 2023 |
| GHRP-6 | 503B | September 29, 2023 |
| MK-677 | 503A; 503B | 503A: September 29, 2023 503B: December 29, 2022 |
| Ipamorelin | 503B | September 29, 2023 |
| Kisspeptin-10 | 503A | September 29, 2023 |
| Compound | Name FDA uses |
|---|---|
| AOD-9604 | AOD-9604 |
| BPC-157 | BPC-157 |
| LL-37 | Cathelicidin LL-37 |
| CJC-1295 | CJC-1295 |
| Dihexa | Dihexa acetate |
| DSIP | Emideltide (DSIP) |
| Epitalon | Epitalon |
| GHK-Cu | GHK-Cu (for injectable routes of administration) |
| Ipamorelin | Ipamorelin acetate |
| KPV | KPV |
| PEG-MGF | Mechano growth factor pegylated (PEG-MGF) |
| Melanotan II | Melanotan II |
| MOTS-C | MOTs-C |
| Selank | Selank acetate (TP-7) |
| Semax | Semax (heptapeptide) |
| Thymosin Alpha-1 | Thymosin-alpha 1 (Ta1) |
| TB-500 | Thymosin beta-4, fragment (LKKTETQ), also known as TB-500 |
This changed in July 2026, and most published answers predate it
On 23 and 24 July 2026 the FDA Pharmacy Compounding Advisory Committee evaluated seven of the compounds in this catalog for inclusion on the 503A Bulks List, and voted in favour of four of them on the first day. The committee advises rather than decides. Its vote adds nothing to the 503A list by itself, and any addition would require a proposed rule, a public comment period, and a final rule. It is recorded here because the widely repeated statement that these compounds were banned from compounding in 2023 no longer describes the current position.
| Compound | Use evaluated | Outcome |
|---|---|---|
| BPC-157 | Ulcerative colitis | Recommended for the list, 8 for, 6 against, 1 abstention |
| KPV | Wound healing and inflammatory conditions | Recommended for the list, 8 for, 6 against, 1 abstention |
| TB-500 | Wound healing | Recommended for the list, 8 for, 6 against, 1 abstention |
| MOTS-C | Obesity and osteoporosis | Recommended for the list, 7 for, 5 against, 2 abstentions |
| DSIP | Opioid withdrawal, chronic insomnia, and narcolepsy | Evaluated on 2026-07-24. No tally reported by the sources cited below. |
| Semax | Cerebral ischemia, migraine, and trigeminal neuralgia | Evaluated on 2026-07-24. No tally reported by the sources cited below. |
| Epitalon | Insomnia | Evaluated on 2026-07-24. No tally reported by the sources cited below. |
Frequently asked questions
What is the difference between research-grade and medical-grade peptides?
Neither is a regulatory grade, and neither term is defined in United States drug law. The difference that carries legal weight is the supply lane. An approved prescription drug is manufactured under current Good Manufacturing Practice against a filed specification and carries an approved label. A compounded preparation is made by a licensed pharmacy or a registered outsourcing facility and is not FDA-approved. A research chemical is sold under a not-for-human-consumption label, which is what keeps the sale outside drug regulation, and no regulator has assessed its identity, purity or safety for human use.
Does research-grade mean lower purity?
Not necessarily, and that is the trap in the phrase. A research chemical may test at high purity by high-performance liquid chromatography and still carry no assurance of sterility, endotoxin load, correct fill weight or stability, because nobody with regulatory authority inspected the facility that made it. Purity and pharmaceutical quality are different claims, and a certificate of analysis speaks to the first one only.
Which peptides has the FDA named as presenting significant safety risks in compounding?
FDA publishes the substances it has placed in category 2 of its interim compounding policy, along with the risk it identified for each. It separately publishes substances that were nominated for the bulks lists and later withdrawn by the nominator. Both lists name individual peptides, and the tables on this page show which compounds in this catalog appear on them, with the dates FDA recorded.
Sources
Open this guide on PeptideHelper.org for the interactive version with the full guide series navigation.